Zymeworks Scores FDA Fast Track for FRα-Targeting ZW191 in Ovarian Cancer
Zymeworks secured FDA Fast Track designation for its FRα-targeting antibody-drug conjugate ZW191 in treating advanced platinum-resistant ovarian cancer. ZW191’s design includes a topoisomerase-1 inhibitor payload targeting tumors expressing FRα in roughly 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers and about 70% of lung adenocarcinomas.
1. FDA Grants Fast Track Designation
In March 2026 the FDA granted Fast Track designation to ZW191 for treatment of advanced or metastatic platinum-resistant ovarian cancer, expediting development and review timelines for this serious indication.
2. ADC Mechanism and Proprietary Payload
ZW191 is an antibody-drug conjugate engineered to target folate receptor-α (FRα) on tumor cells, internalize and release the novel topoisomerase-1 inhibitor payload ZD06519 to induce cancer cell death without requiring biomarker selection.
3. Phase 1 Clinical Trial Design
The ongoing Phase 1 trial (NCT06555744) is enrolling patients with advanced solid tumors to assess ZW191’s safety, tolerability, pharmacokinetics and preliminary anti-tumor activity, with data informing subsequent development strategies.
4. FRα Expression Across Tumor Types
FRα is expressed in approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers and around 70% of lung adenocarcinomas, supporting potential expansion of ZW191 across multiple tumor types.